The main research focus of the Department of Neuroradiopharmaceuticals is the development and evaluation of radiolabelled ligands (radiotracers) in order to investigate brain functions in living organism. The application of the radiotracers provides images of transport, metabolic and neurotransmission processes on the molecular level. The method used in humans to acquire such information is positron emission tomography (PET), the most sensitive and specific method available at present. Through integration of chemical/radiochemical, pharmaceutical/radiopharmaceutical, biochemical and radiopharmacological basic research, computational chemistry and with the aid of nuclear medicine diagnostic, a new approach in neuroscience will be made available. The foremost importance of this approach would be the monitoring of the therapy of glioblastoma or brain diseases such as neurodegeneration. An example for the whole process of radiotracer development from the idea to clinical use was documented in a video of Beilstein-TV.